CTNM vs. AKBA, VNDA, XERS, HOWL, VSTM, RAPT, FHTX, PYXS, NBTX, and VRCA
Should you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Akebia Therapeutics (AKBA), Vanda Pharmaceuticals (VNDA), Xeris Biopharma (XERS), Werewolf Therapeutics (HOWL), Verastem (VSTM), RAPT Therapeutics (RAPT), Foghorn Therapeutics (FHTX), Pyxis Oncology (PYXS), Nanobiotix (NBTX), and Verrica Pharmaceuticals (VRCA). These companies are all part of the "pharmaceutical preparations" industry.
Contineum Therapeutics (NASDAQ:CTNM) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.
Contineum Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -22.99%.
Contineum Therapeutics has higher earnings, but lower revenue than Akebia Therapeutics.
Contineum Therapeutics presently has a consensus price target of $28.00, indicating a potential upside of 77.10%. Akebia Therapeutics has a consensus price target of $5.00, indicating a potential upside of 313.22%. Given Akebia Therapeutics' higher probable upside, analysts plainly believe Akebia Therapeutics is more favorable than Contineum Therapeutics.
Akebia Therapeutics received 407 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 63.96% of users gave Akebia Therapeutics an outperform vote.
33.9% of Akebia Therapeutics shares are owned by institutional investors. 3.8% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Akebia Therapeutics had 10 more articles in the media than Contineum Therapeutics. MarketBeat recorded 14 mentions for Akebia Therapeutics and 4 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.53 beat Akebia Therapeutics' score of 0.39 indicating that Contineum Therapeutics is being referred to more favorably in the media.
Summary
Akebia Therapeutics beats Contineum Therapeutics on 6 of the 10 factors compared between the two stocks.
Get Contineum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Contineum Therapeutics Competitors List
Related Companies and Tools
